Maxim Initiates Buy Rating on Rein Therapeutics with $4 Price Target as LTI-03 Advances

Maxim highlights reduced risk and strong progress on LTI-03 for idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway with topline data expected by end of 2027.